Vita 34 AG
V3V
ISIN DE000A0BL849 / Valor 2333201
Vita 34 AG
UMushroom community rating:
About company
Vita 34 AG is a full-service provider in the field of cell banking and stem cell banking, offering services from removal and processing to preservation and delivery. With approximately 100 employees, the company specializes in storing stem cells for medical purposes, providing a crucial service for individuals looking to safeguard their health and well-being. Vita 34 AG's expertise in this niche area of healthcare positions them as a key player in the industry, catering to the growing demand for personalized medical solutions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (16.09.2025):
Vita 34 AG has reported a strong first quarter in 2024, showcasing significant increases in earnings and operating cash flow. The company's revenues and EBITDA have grown compared to Q1 2023, driven by robust demand for contract renewals and a shift towards higher-value product offerings.
Revenue Growth
Revenues for Vita 34 AG amounted to EUR 18.6 million in Q1 2024, marking a 3.6% increase compared to EUR 17.9 million in Q1 2023.
Surge in B2C Services
The net amount of invoiced services to the end consumer business (B2C) rose significantly by 13.6%, reaching EUR 18.0 million in Q1 2024 from EUR 15.9 million in the previous year. Annually recurring payments contributed EUR 5.7 million, up from EUR 5.2 million.
EBITDA Improvement
Vita 34 AG's EBITDA increased substantially to EUR 1.5 million in Q1 2024, up from EUR 0.3 million in the first quarter of 2023. This improvement is attributed to continued cost discipline and the positive comparison to reduced earnings in the prior year.
Operating Cash Flow
The company's operating cash flow saw a significant increase, reaching EUR 4.0 million in Q1 2024, despite a decrease in cash and cash equivalents by EUR 15.1 million due to credit line repayments.
Positive 2024 Outlook
The Management Board of Vita 34 AG reaffirms its annual outlook, expecting revenues between EUR 81 and 88 million and EBITDA between EUR 6.5 and 8.0 million for 2024, based on stable exchange rates.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
121 M
Market cap (USD)
662
Daily traded volume (Shares)
4.08 / 4
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
